

PRESCRIBING INFORMATION

ACETAZOLAMIDE

Acetazolamide Tablets BP

250 mg

Carbonic Anhydrase Inhibitor

**AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Control Number: 214651**

**DATE OF PREPARATION:
June 03, 2010**

**DATE OF REVISION:
May 8, 2018**

PRESCRIBING INFORMATION

ACETAZOLAMIDE

Acetazolamide Tablets BP

250 mg

THERAPEUTIC CLASSIFICATION

Carbonic Anhydrase Inhibitor

INDICATIONS

To decrease ocular aqueous humor secretion in glaucoma (chronic, simple and secondary types). Also used as an adjunct in the treatment of selected cases of epilepsy. To alkalinize the urine in selected cases of salicylate overdosage.

CONTRAINDICATIONS

Depressed sodium and/or potassium blood levels, in renal failure, adrenal gland failure, metabolic acidosis, and some cases of hepatic cirrhosis, severe glaucoma due to peripheral anterior synechias or in hemorrhagic glaucoma. Long term use in chronic non-congestive angle closure glaucoma is contra-indicated.

Studies on acetazolamide in mice and rats have consistently demonstrated embryocidal and teratogenic effects at doses in excess of 10 times the human dose. There is no evidence of these effects in humans; however, acetazolamide should not be used in pregnancy, unless the anticipated benefits outweigh these potential hazards and are not attainable in other ways.

PRECAUTIONS

Increasing the dose does not increase, and may often decrease the diuresis, and may yet produce drowsiness and/ or paresthesia.

The patient should be cautioned to report any unusual skin rash. Severe Cutaneous Adverse Reactions such as Stevens Johnsons Syndrome, Erythema Multiforme, Toxic Epidermal Necrolysis and Acute Generalised Exanthematous Pustulosis may occur with acetazolamide. Hypersensitivity reactions may recur if a sulphonamide or sulphonamide derivative is re-administered, irrespective of the route of administration. If signs of hypersensitivity reactions or other serious reactions occur, acetazolamide must be discontinued.

ADVERSE EFFECTS

Metabolic acidosis and hypokalemia may occur during prolonged acetazolamide therapy.

Adverse reactions common to all sulfonamide derivatives including fever, rash (including Stevens Johnsons Syndrome, Erythema Multiforme, Toxic Epidermal Necrolysis and Acute Generalised Exanthematous Pustulosis), crystalluria, renal calculus, bone marrow depression, thrombocytopenic purpura, hemolytic anemia, leukopenia, pancytopenia, and agranulocytosis may occur. If such reactions occur, discontinue therapy and institute appropriate measures.

Untoward effects during short term therapy are said to be minimal. Those noted include paresthesias, some loss of appetite, polyuria and occasional instances of drowsiness and confusion. Other occasional adverse reactions include urticaria, melena, hematuria, glycosuria, hepatic insufficiency, flaccid paralysis and convulsions.

Transient myopia has been reported. This condition invariably subsided upon the diminution or discontinuation of the medication.

DOSAGE

Chronic simple (open angle) glaucoma: 250 mg. 1 to 4 times daily. A complementary effect has been noted when acetazolamide was used with miotics or mydriatics as the case demanded.

Secondary glaucoma and preoperative treatment of some cases of acute congestive (closed angle) glaucoma: 250 mg every 4 hours. Epilepsy: 8 to 30 mg/kg (375 to 1000 mg) daily in divided doses. To alkalinize the urine: 250 mg every 4 to 6 hours.

AVAILABILITY OF DOSAGE FORMS

Each white, scored, compressed tablet contains: acetazolamide BP 250 mg. Identified 250. Bottles of 100 and 500.

REFERENCES

1. Kim S. Park H. Jee Y. Park H. Jung J. Park J. Lee J. Kang H. Carbonic anhydrase inhibitors-induced severe cutaneous adverse reactions: Analysis of Korean SCAR registry database 2010-2015. Allergy: European Journal of Allergy and Clinical Immunology (2017) 72 Supplement 103 (122-123). Date of Publication: 1 Aug 2017.
2. Her Y. Kil M.S. Park J.H. Kim C.W. Kim S.S. Stevens-Johnson syndrome induced by acetazolamide. Journal of Dermatology (2011) 38:3 (272-275). Date of Publication: March 2011.

3. Ogasawara K. Tomitsuka N. Kobayashi M. Komoribayashi N. Fukuda T. Saitoh H. Inoue T. Ogawa A. Stevens-Johnson syndrome associated with intravenous acetazolamide administration for evaluation of cerebrovascular reactivity. *Neurologia Medico-Chirurgica* (2006) 46:3 (161-163). Date of Publication: March 2006.
4. Benamara-Levy M, Haccard F, Jonville Bera AP, Machet L. Acute generalized exanthematous pustulosis due to acetazolamide: negative on patch testing and confirmed by delayed-reading intradermal testing. *Clin Exp Dermatol*. 2014 Mar; 39(2):220-2.
5. Jachiet M. Bellon N. Assier H. Amsler E. Gaouar H. Pecquet C. Bourrain J.L. Bégon E. Chosidow O. Francès C. Ingen-Housz-Oro S. Soria A. Cutaneous adverse drug reaction to oral acetazolamide and skin tests. *Dermatology* (2013) 226:4 (347-352). Date of Publication: 2013.
6. Ha J.H. Song J.Y. Kim H.O. Kim J.W. A case of Stevens-Johnson syndrome caused by acetazolamide. *Korean Journal of Dermatology* (2003) 41:2 (248-250). Date of Publication: 1 Feb 2003.
7. Ogoshi M, Yamada Y, Tani M: Acute generalized exanthematic pustulosis induced by cefaclor and acetazolamide. *Dermatology* 1992;184: 142–144.
8. Kim J.W. Kim S.T. Song D.H. A clinical observation of the patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in Jeju island. *Korean Journal of Dermatology* (2004) 42:5 (579-591). Date of Publication: May 2004.